In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Denali could pay big in new F-star deal; holds option to acquire

Executive Summary

Denali Therapeutics Inc. and F-star GMBH, through its newly created asset-centric vehicle F-star Gamma Ltd., entered into a collaboration to discover and develop new neurological disease therapies that can be delivered into the CNS across the blood-brain barrier. Denali also gained an option to acquire F-star Gamma prior to Phase I trials.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing
    • Includes M&A Option
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register